ABCL vs EXAS · rev $12.4M vs rev $2.76B
Abcellera Biologics Inc (ABCL) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
ABCL currently screens at market cap $1.12B. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the ABCL and EXAS stock pages for the full models.
Not investment advice.